REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Share News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.00
Bid: 9.00
Ask: 9.50
Change: -0.65 (-6.74%)
Spread: 0.50 (5.556%)
Open: 9.50
High: 10.20
Low: 9.00
Prev. Close: 9.00
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: CEO departs after GLI Finance becomes Sancus

Wed, 02nd Jun 2021 16:02

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Wednesday and not separately reported by Alliance News:

----------

Sancus Lending Group Ltd - Guernsey-based alternative property finance - Andy Whelan resigns as chief executive officer, leaving on June 30, when he will be replaced by Rory Mepham as interim CEO. Mepham currently is in charge of funding and origination, having joined the company in January. Dan Walker, who currently is chief operating officer and managing director of Sancus UK, will become deputy CEO. Walker joined the company in 2018 from Lloyds Banking Group PLC, where he was director of Strategic Transactions. The changes follow refinancing and restructuring at Sancus, including renaming itself from GLI Finance Ltd, which was approved by shareholders earlier this month. This is to reflect its focus on the property bridging and development finance activities of the Sancus subsidiary.

----------

Cambridge Cognition Holdings PLC - Cambridge, England-based neuroscience technology - Adds Chief Financial Officer Mick Holton to board as executive director, effective immediately. Holton joined Cambridge Cognition in January from Biome Technologies PLC, where he was interim CFO. He previously worked for what is now Walgreens Boots Alliance Inc.

----------

Dispersion Holdings PLC - investor in decentralised finance, which uses blockchain and cryptocurrencies to remove financial intermediaries from transactions - Adds CFO Nick Lyth to board, effective immediately. Dispersion listed on Aquis Stock Exchange in late April, raising GBP9 million in its initial public offering and GBP2.2 million in pre-IPO fundraisings.

----------

e-Therapeutics PLC - Oxford, England-based drug discovery - Hires Alison Gallafent as head of Intellectual Property. Gallefent was head of IP at fellow AIM listing Silence Therapeutics PLC and also worked at Merck & Co Inc and Glaxo Wellcome.

----------

SDX Energy PLC - gas production in Egypt and exploration & development in Morocco - Amr Al Menhali will retire as director at annual general meeting on June 25, having left shareholder Waha Capital. Al Manhali had joined the SDX board back in September 2019, having been named CEO of Waha, which is SDX's largest shareholder, with a 19.5% stake.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
20 Mar 2018 16:14

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 21 March KingfisherFull Year ResultsAlpha FXFull Year In SportFull 22

Read more
9 Jan 2017 08:49

E-Therapeutics Hires Amgen Director As New Chief Executive

Read more
6 Oct 2016 11:23

DIRECTOR DEALINGS: e-Therapeutics Non-Executive Acquires Shares

Read more
14 Sep 2016 11:23

e-Therapeutics Development Director Steve Self To Step Down

Read more
13 Jul 2016 09:13

E-Therapeutics Chairman Takes On Executive Duties As CEO Steps Down

Read more
1 Jun 2016 08:03

e-Therapeutics Offer For Searchbolt Now Wholly Unconditional

Read more
25 May 2016 08:18

e-Therapeutics Focused On Validation Of Drug Discovery Platform

Read more
18 May 2016 15:05

AGM, EGM Calendar - Week Ahead

Read more
12 May 2016 11:13

DIRECTOR DEALINGS: E-Therapeutics Non-Executive Acquires Shares

Read more
11 May 2016 09:06

e-Therapeutics To Buy Searchbolt For GBP2.3 Million (ALLISS)

Read more
22 Mar 2016 11:40

E-Therapeutics Loss Widens As Active Projects Increase

Read more
15 Mar 2016 16:15

Earnings, Trading Statements Calendar - Week Ahead

Read more
15 Feb 2016 10:43

WINNERS & LOSERS SUMMARY: Reckitt Benckiser Results Please Investors

Read more
15 Feb 2016 09:45

E-Therapeutics depression drug trials miss targets

(ShareCast News) - Drug trials results for e-Therapeutics' depression treatment were not as successful as had been hoped, sending shares in the company sharply lower. Phase IIb clinical trials of the company's ETS6103 product did not achieve the aim of matching the efficacy of existing tricyclic ant

Read more
15 Feb 2016 08:20

E-Therapeutics Shares Drop As ETS6103 Trials Miss Primary Endpoint

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.